ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical research"

  • Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting

    Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression

    Deepak R. Jadon1, Gavin Shaddick2, William Tillett1, Graham Robinson3, Charlotte Cavill1, Nicola Waldron1, Eleanor Korendowych1 and Neil J McHugh4, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Mathematics, University of Bath, Bath, United Kingdom, 3Royal United Hospital, Bath, United Kingdom, 4Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

    Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
  • Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure

    Philip J. Mease1, Roy Fleischmann2, Jurgen Wollenhaupt3, Atul A. Deodhar4, Dafna D. Gladman5, Bengt Hoepken6, Luke Peterson7 and Désirée M. van der Heijde8, 1Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 2Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 3Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 4Oregon Health and Sciences University, Portland, OR, 5University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6UCB Pharma, Monheim, Germany, 7Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
  • Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression

    Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir*3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

    Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
  • Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting

    Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System

    Esi M. Morgan DeWitt1, Kimberly Barnett2, Wen-Hung Chen3, Jennifer Farrell4, Dennis Revicki5, Adam Carle6, Karon Cook7, Kenneth Goldschneider8, Carlton Dampier9, David D. Sherry10 and Susmita Kashikar-Zuck2, 1Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Evidera, Bethesda, MD, 4Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Outcomes Research, Evidera, Bethesda, MD, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, 10Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…
  • Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting

    Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)

    Ivan Foeldvari1, Gerd Horneff2, Kirsten Minden3, Ralf Trauzeddel4, J B. Kuemmerle-Deschner5, Klaus Tenbrock6, Gerd Ganser7 and Hans-Iko Huppertz8, 1Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 2Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 3Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, 4Pediatrics, Helios Clinics, Berlin, Germany, 5Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 6University Aachen, Aachen, Germany, 7Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 8Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany

    Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
  • Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting

    Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials

    Morten Asser Karsdal1, Anne C. Bay-Jensen2, Asger Bihlet3, Peter Alexandersen4, Inger Byrjalsen3, Jeppe Andersen3, Bente J. Riis3 and Claus Christiansen3, 1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Center for Clinical and Basic Research, Vejle, Denmark

    Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…
  • Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting

    Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Philip J. Mease1, Roy Fleischmann2, Owen Davies3, Tommi Nurminen4 and Désirée van der Heijde5, 1Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 2Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim, Germany, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…
  • Abstract Number: 138 • 2013 ACR/ARHP Annual Meeting

    Long Term Outcomes In Fibromyalgia

    Lesley M. Arnold1 and Thomas Blom2, 1Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, 2Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: There are few studies on the long-term prognosis of fibromyalgia. This study assessed the natural history of fibromyalgia in patients receiving usual medical care…
  • Abstract Number: 2544 • 2013 ACR/ARHP Annual Meeting

    Serum Mediated Phagocytosis Of Necrotic Material By Polymorphonuclear Leukocytes May Be Used As a Tool To Predict Clinical Manifestations In Systemic Lupus Erythematosus

    Michele Compagno1, Birgitta Gullstrand2, Andreas Jönsen3, Lennart Truedsson2, Gunnar Sturfelt4 and Anders A. Bengtsson3, 1Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, 2Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, 3Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, 4Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden

    Background/Purpose: Polymorphonuclear (PMNs) leukocytes with engulfed necrotic cell material (NCM), as formerly used in the LE-cell test, are frequently seen in SLE and associated to…
  • Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting

    Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients

    Paul Studenic1, Josef S. Smolen2,3 and Daniel Aletaha4, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2PsAID taskforce, EULAR, Zurich, Switzerland, 32nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
  • Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting

    Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer.  A Prospective Study

    Daniel Wendling1, Helene Letho-Gyselinck1, Xavier Guillot2, Clément Prati3 and Xavier Pivot4, 1Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 2Department of Rheumatology, CHRU Besançon, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France, 4Oncology, CHRU Besançon, Besançon, France

    Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…
  • Abstract Number: 1925 • 2013 ACR/ARHP Annual Meeting

    Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London

    Genevieve Casey1, Carey Tierney2, Hasan Tahir3, Simon Donnelly3 and Judith Bubbear3, 1Barts and the London Medical School, London, United Kingdom, 2Whipps Cross Clinical Research Unit, Barts Health NHS Trust, London, United Kingdom, 3Rheumatology, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Compared to patient satisfaction with general medical care little is known about patient satisfaction within clinical trials. Clinical trials are a time and resource…
  • Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting

    Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial

    In-Ho Song1, Kay-Geert A. Hermann2, Hildrun Haibel1, Christian Althoff3, Denis Poddubnyy4, Joachim Listing5, Anja Weiss6, Ekkehard Lange7, Bruce Freundlich8, Martin Rudwaleit9 and Joachim Sieper4, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Berlin, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany, 7BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, 8University of Pennsylvania, Philadelphia, PA, 9Endokrinologikum, Berlin, Germany

    Background/Purpose:     < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
  • Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting

    Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis

    Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
  • Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier

    Masahiro Tada1, Tatsuya Koike2, Akihiro Tamori3, Tadashi Okano1, Yuko Sugioka1, Kenji Mamoto1, Kentaro Inui4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology